Cns Pharmaceuticals Inc (CNSP)
CNS Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company focused on developing anti-cancer drug candidates for brain and central nervous system tumors. Its pipeline includes TPI 287 and Berubicin, both of which are being evaluated in Phase 2 clinical trials for glioblastoma and other CNS malignancies. The company also has a license agreement with Cortice Biosciences, Inc. CNS Pharmaceuticals was incorporated in 2017 and is headquartered in Houston, Texas. Its common stock is listed on the NASDAQ exchange under the symbol CNSP.
Stock Summary
Fair Value
Profitability & Growth
Quality & Risk
Events & Dividends
Technical Outlook
FAQ
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
Data update note:
Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-CNSP
|
$5.37
|
0.3% Upside
|
Fair
|
$10
|
86.9% Upside
|
Bargain
|
Weak
|
—
|
—
|
—
|
0.0%
|
August 17, 2026
|
-0.5x
|
110.6x
|
—
|
8.038 M
|
5.1 M
|
2.8%
|
99.5%
|
-42.5
|
—
|
92.5%
|
